For instance, even with aggressive anti‐VEGF treatment around 50% of patients have persistent macular oedema and moderate to no improvement in their visual acuity (Ford et al., 2013), suggesting a different treatment plan could have been more beneficial. The gene discussed is VEGFA; the disease is macular retinal edema.